press release

May 5, 2017

Alnylam Licenses Fundamental Patent In RNA Interference To Cell Signaling Technology Cambridge, MA January 13, 2004 Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that its German affiliate, Ribopharma AG, has granted Cell Signaling Technology, Inc. a non exclusive license to provide research products under a fundamental patent in RNA interference (RNAi). The licensed patent is the first and ...

press release

May 5, 2017

Alnylam Expands Management Team with New AppointmentsCAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 16, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the expansion of its management team with the appointment of two individuals to key positions. The company named Stuart Pollard, Ph.D., to the position of Vice President, Scientific and Business Strategy, and Donna Ward, Ph.D., to ...

press release

May 5, 2017

Alnylam Receives Milestone Payment from Roche Related to Advancement of RNAi TherapeuticsCAMBRIDGE, Mass., Jan 06, 2010 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has received a milestone payment from its partner Roche (SIX: RO, ROG; OTCQX: RHHBY) related to initiation of pre IND (investigational new drug application) studies for ...

press release

May 5, 2017

Alnylam and Collaborators Discover Key Mechanism for Delivery of RNAi TherapeuticsCAMBRIDGE, Mass., Jan 08, 2010 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre clinical research was presented at the ...

press release

May 5, 2017

Alnylam and Collaborators Present Data from Multiple Pre Clinical and Clinical Programs at RNAi Keystone SymposiumCAMBRIDGE, Mass., Jan 19, 2010 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it presented data from multiple pre clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January ...

press release

May 5, 2017

Alnylam Announces Top Line Results of Phase IIb Clinical Trial of ALN RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) InfectionCAMBRIDGE, Mass. (BUSINESS WIRE) May. 30, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today top line results from a Phase IIb trial with ALN RSV01 for the treatment of respiratory syncytial ...

press release

May 5, 2017

Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi TherapeuticsCAMBRIDGE, Mass. & MADRID (BUSINESS WIRE) Nov. 16, 2011 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced today that Alnylam has granted ...

press release

May 5, 2017

Alnylam Announces Publication of Pre clinical Results with ALN HTT, an RNAi Therapeutic for the Treatment of Huntington's Disease, in Experimental NeurologyCAMBRIDGE, Mass., Dec 28, 2011 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of promising pre clinical results in Experimental Neurology (doi:10.1016/j.expneurol.2011.11.020) related to its ALN HTT ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and 2010 Financial ResultsCAMBRIDGE, Mass., Feb 17, 2011 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and year ended December 31, 2010, and company highlights. "The RNAi therapeutics field evidenced significant changes in 2010, but for Alnylam, the ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports First Quarter 2011 Financial ResultsCAMBRIDGE, Mass., May 02, 2011 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2011, and company highlights. "During the first quarter and recent period of 2011, we made important progress in advancing our clinical pipeline and in ...